CV Sciences (CVSI) Total Non-Current Liabilities (2013 - 2024)
CV Sciences' (CVSI) quarterly Total Non-Current Liabilities came in at $6.1 million in Q4 2024, down 0.97% year-on-year from $6.2 million in Q1 2024, and little changed quarter-over-quarter from $6.2 million in Q3 2024.
CV Sciences (CVSI) Total Non-Current Liabilities (2013 - 2024) Analysis & Trends
CV Sciences has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $6.1 million for Q4 2024.
- Total Non-Current Liabilities for Q4 2024 came in at $6.1 million, down 0.97% year-over-year; the trailing twelve-month figure through Dec 2024 was $6.1 million (down 0.97% YoY), and the FY2024 annual result was $6.1 million, down 0.97% from the prior year.
- Total Non-Current Liabilities came in at $6.1 million for Q4 2024 at CV Sciences, roughly flat from $6.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $23.7 million in Q2 2020 to a low of $6.0 million in Q1 2024.
- The 4-year median for Total Non-Current Liabilities is $9.9 million (2022), against an average of $12.8 million.
- Across the five-year window, Total Non-Current Liabilities soared 36.51% in 2020 and tumbled 54.18% in 2023, its largest moves.
- CV Sciences' Total Non-Current Liabilities stood at $19.4 million in 2020, then sank by 30.39% to $13.5 million in 2022, then sank by 54.18% to $6.2 million in 2023, then decreased by 0.97% to $6.1 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $6.1 million (Q4 2024), $6.2 million (Q3 2024), and $6.3 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | CV Sciences | - | - | 1.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6.13 Mn |
| Sep 30, 2024 | 6.16 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 6.19 Mn |
| Dec 31, 2022 | 13.51 Mn |
| Dec 31, 2020 | 19.41 Mn |
| Sep 30, 2020 | 18.96 Mn |
| Jun 30, 2020 | 23.71 Mn |
| Mar 31, 2020 | 21.94 Mn |
| Dec 31, 2019 | 23.13 Mn |
| Sep 30, 2019 | 23.30 Mn |
| Jun 30, 2019 | 17.37 Mn |
| Mar 31, 2019 | 17.51 Mn |
| Dec 31, 2018 | 6.79 Mn |
| Sep 30, 2018 | 4.05 Mn |
| Jun 30, 2018 | 4.09 Mn |
| Mar 31, 2018 | 3.86 Mn |
| Dec 31, 2017 | 5.26 Mn |
| Jun 30, 2017 | 5.01 Mn |